StockData

Annovis Bio vs BioVie

ANVS and BIVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANVS and BIVI compare

Annovis Bio is the larger company, worth 4.2 times as much as BioVie ($31.7M against $7.5M).

BioVie scores higher on the StockData Score (5 against 4 for Annovis Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANVSBIVI
Size and price
Market cap$31.7M$7.5M
Share price$0.743$0.995
Change, 1 year−68.2%−33.6%
Change, 5 years−97.1%−99.8%
Beta (5Y)3.47−0.37
Employees813
StockData Score
Total score45 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score44
Dividend score00
Valuation
P/B–0.7×
Profitability
Return on equity−704%−151% (better)
Return on invested capital–−1297%
Financial health
Debt / equity–0.00
Interest coverage–−1265.4×
Current ratio–3.59
Altman Z-score−19.15 (better)−40.05
Piotroski F-score3 (better)1
Dividends and buybacks
Buyback yield–−139%
Shareholder yield0.00% (better)−139%
Ownership
Held by institutions25.5%51.2%
Held by insiders23.1%48.6%
Insider net buying, 12 months$6.8M (better)$52.0K
Short interest, % of float16.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.